Blog

Raffaele Colombo: Sacituzumab Tirumotecan Versus Docetaxel in EGFR-Mutated Advanced NSCLC

Raffaele Colombo/LinkedIn

Jun 12, 2025, 10:54

Raffaele Colombo: Sacituzumab Tirumotecan Versus Docetaxel in EGFR-Mutated Advanced NSCLC

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:

“OptiTROP-Lung03 published on The BMJ: sacituzumab tirumotecan (sac-TMT) versus docetaxel for previously treated EGFR-mutated advanced NSCLC.

sac-TMT vs docetaxel
ORR: 45% vs 16%
PFS: 6.9 vs 2.8 months
OS: NR, HR=0.49

(data also presented at ASCO25).”

Title: Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Authors: Wenfeng Fang, Xingya Li, Qiming Wang, Xiangjiao Meng, Wei Zheng, Longhua Sun, Wenxiu Yao, Wu Zhuang, Yun Fan, Minglei Zhuo, Yongzhong Luo, Zhiye Zhang, Xia Song, Runxiang Yang, Jiacheng Yang, Xiaoping Jin, Yina Diao, Junyou Ge, Li Zhang

Read The Full Article at The BMJ.

Raffaele Colombo: Sacituzumab Tirumotecan Versus Docetaxel in EGFR-Mutated Advanced NSCLC

More posts featuring Raffaele Colombo.

ASCO25 cancer Jiacheng Yang Junyou Ge Li Zhang Longhua Sun Minglei Zhuo NSCLC OncoDaily Oncology Qiming Wang Raffaele Colombo Runxiang Yang The BMJ Wei Zheng Wenfeng Fang Wenxiu Yao Wu Zhuang Xia Song Xiangjiao Meng Xiaoping Jin Xingya Li Yina Diao Yongzhong Luo Yun Fan Zhiye Zhang

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology

How Artificial Intelligence Is Transforming Cancer Care in 2025: Diagnosis, Treatment, Clinical Trials, and Screening

Inside ASCO25 Exhibition - Who did it the best?

Douglas Flora: Fighting Cancer with Heart